News | Left Atrial Appendage (LAA) Occluders | January 18, 2018

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib

Biosense Webster, Inc. launches U.S. clinical study to evaluate the safety and efficacy of the WaveCrest Left Atrial Appendage Occlusion System

 

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib

January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled the first patient in the WaveCrest Investigational Device Exemption (IDE) Trial. The study will evaluate the safety and effectiveness of the WaveCrest Left Atrial Appendage Occlusion (LAAO) System in closure of the Left Atrial Appendage (LAA) and evaluate reduction of embolic stroke in atrial fibrillation (AFib) patients who cannot tolerate chronic Oral Anticoagulation Therapy (OAC).

The first patient was treated at New York University (NYU) Hospital by Larry Chinitz, M.D., a cardiac electrophysiologist and director of NYU Langone’s Heart Rhythm Center in New York City. The trial will enroll 1,250 patients at approximately 90 hospitals, and follow them for five years.

“The WaveCrest System is designed to enable physicians to close the heart’s LAA, where most stroke-causing blood clots occur,” said Chinitz. “For patients with AFib seeking an alternative to anticoagulants or blood thinners, this may be an important procedural option that could reduce the risk of stroke and save lives.”

According to the American Stroke Association, people with AFib have a five times higher risk of stroke than the general population. The Centers for Disease Control and Prevention (CDC) estimates 87 percent of all strokes are ischemic strokes, in which blood flow to the brain is blocked by the formation of a clot. Stroke is one of the most devastating and debilitating diseases, costing the United States an estimated $34 billion each year.

“Preventing and reducing the risk of stroke in AFib patients is a significant unmet need,” said Shlomi Nachman, company group chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “We are committed to investing in meaningful innovation and are excited by the prospect of bringing the WaveCrest System to the U.S. market so that more patients can benefit.”

The study is a prospective, multicenter, randomized, active controlled clinical trial of the WaveCrest Left Atrial Appendage Occlusion System compared to an existing FDA-approved LAA Closure Device for the reduction in risk of embolic stroke in subjects with non-valvular atrial fibrillation.

Although the device is under clinical study and not approved for use in the US, the WaveCrest Device is CE Mark approved and available in Europe.

For more information:  www.biosensewebster.com

 

Related Content

Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders | October 16, 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc.
Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

News | Left Atrial Appendage (LAA) Occluders | December 18, 2019
December 18, 2019 — Append Medical, developer of a novel left atrial app
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
News | Left Atrial Appendage (LAA) Occluders | August 28, 2019
AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-generation...